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Abstract 
Background 
Emerging evidence supports the role of cell-derived microparticles (MPs) in the 
pathophysiology of acute coronary syndrome (ACS). 
Objectives  
To explore the relationship between coronary and systemic MP levels, investigate the 
correlation between MPs, inflammatory markers and Troponin T in patients with ACS. 
Methods  
Thirty seven patients with ACS scheduled for percutaneous coronary interventions (PCI) 
were studied. Eleven patients with stable angina (SA) were included as a control group. 
AnnexinV+MPs (AnV+MPs) and activated platelet-monocyte aggregates (PMA) from right 
atrium (RA) and culprit coronary artery (CO) distal to culprit lesion were measured using 
flow cytometry. High sensitivity C- reactive protein (CRP), Interleukin - 6 (IL-6), tumour 
necrosis factor – α (TNF-α), serum amyloid A (SAA) and Troponin T were assayed. 
Results 
Total and cell specific AnV+MP expression were higher in the ACS group in both the CO 
and RA, with greater levels detected in the CO. Platelet activation showed positive 
correlation with Troponin-T and platelet MP in both CO and RA of the ACS group (r=0.4 for 
both; p=0.04 & p=0.03 respectively). Inflammatory markers levels did not differ between the 
ACS and SA patients.  
Conclusions 
Elevated coronary and systemic MP levels and positive correlation of platelet activation with 
Troponin-T and platelet MPs suggest a pathogenic role for MPs in ACS. 
Key words: acute coronary syndrome, microparticles, inflammation, platelet activation and 
myocardial necrosis 
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Background 
Inflammation plays a pivotal role in the pathogenesis of coronary artery disease (CAD) 
(1)controlling not only the evolution of atheromatous plaque but also its propensity for 
rupture or erosion, by altering the matrix composition (2). In addition, inflammation, through 
the activation and differentiation of the inflammatory cells involved, increases the 
thrombogenicity of the plaque’s interior by promoting tissue factor bearing microparticle 
(MP) release with subsequent thrombus formation over the ruptured or eroded plaque (3-5). 
Patients with diseases associated with chronic inflammation such as diabetes mellitus, 
metabolic syndrome and chronic inflammatory autoimmune diseases are at increased risk of 
developing CAD (6). In vivo inflammatory activity can be assessed by measuring C-reactive 
protein (CRP), serum amyloid antigen (SAA) tumour necrosis factor α (TNF-α) and 
Interleukin-6 (IL-6). High levels of inflammatory markers in ACS patients were shown to be 
associated with adverse outcomes (7-10). However, whether or not increased levels of these 
inflammatory markers is merely an association or have any causal relationship with the 
pathogenesis of ACS remains to be established (9,11,12). Furthermore, the source of 
inflammatory markers in ACS is still a matter of debate. It has also been shown that higher 
levels of IL-6 are found in the coronary artery when compared to the systemic arterial 
circulation in patients with ACS (13,14). While elevated inflammatory markers such as CRP 
and SAA, which are synthesised in the liver, indicate systemic inflammation, the above 
evidence supports the concept that intracoronary inflammation may also occur in close to 
proximity to the site of injury. This indicates that assessment of inflammatory markers in the 
peripheral circulation may not truly reflect the true burden of the intracoronary inflammatory 
process. 
Emerging evidence indicates that MPs released from activated cells are potent pro-coagulant 
and pro-inflammatory molecules that may contribute to thrombus formation (3) and 
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endothelial dysfunction (15). It is possible that locally produced MPs may therefore 
contribute to the local coronary inflammatory processes in ACS (16-19), although the exact 
mechanisms are currently poorly understood. Several clinical studies have shown correlation 
between circulating MP levels and clinical outcomes, markers of myocardial damage, 
inflammation and indices of microvascular dysfunction (20-25).  
The aim of this study was therefore to explore the relationship between coronary and 
systemic MP levels, circulating markers of inflammation, and extent of myocardial necrosis 
in patients with ACS. 
 
Methods 
Study population 
Thirty seven ACS patients [23 ST segment elevation myocardial infarction (STEMI), 14 non-
ST segment elevation (NSTEMI)] and 11 stable angina (SA) patients treated with 
percutaneous coronary intervention (PCI) were recruited. The diagnosis of STEMI was based 
on the history of chest pain and ST segment elevation on ECG. NSTEMI was diagnosed 
based on history, ECG changes and Troponin T value > 0.03 ng/l (26). Patients with STEMI 
underwent primary PCI and patients with NSTEMI had PCI in line with recommended 
guidelines. SA patients were admitted electively for PCI after having undergone out patient 
review and investigations. The local ethics committee (LREC London) granted permission to 
undertake the study. Patients with history of prior coronary artery bypass graft surgery and 
those who received Glycoprotein IIb/IIIa antagonists prior to blood sampling were excluded 
from the study. 
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Coronary angiography, PCI and blood sampling 
STEMI cohort was loaded with 300 mg of Aspirin and 600 mg of Clopidogrel prior to PCI. 
NSTEMI patients received 300mg Aspirin followed by 75mg once daily (OD); 300mg 
Clopidogrel followed by 75mg OD and low molecular weight heparin prior to PCI. SA 
patients were treated with aspirin 75mg OD and clopidogrel 75mg OD for at least 7 days 
prior to PCI. 
Coronary angiography was carried out through trans femoral access. Right atrial blood 
samples were obtained using a 5F multipurpose catheter (5F, Cordis ®, internal diameter 
0.11cm) via the femoral vein. Left and right coronary artery angiography was performed with 
a 5F Judkin’s left 4 and right 4 diagnostic catheters (Cordis ®, internal diameter 0.11cm). 
Following diagnostic angiography the culprit lesion was identified and weight adjusted 
unfractionated heparin was given prior to advancing the guide wire to achieve an activated 
clotting time (ACT) of 200 and 250 sec. After wiring of the culprit lesion an aspiration 
catheter (Medtronic ® Export catheter, internal diameter 0.10 cm) was advanced distal to the 
culprit lesion and 10 millilitres (mls) of blood was aspirated. Catheters with similar internal 
diameter were used for blood sample collection to minimise shear stress related in vitro 
platelet activation. PCI was performed according to standard procedures following blood 
sampling. 
 
MP identification and characterization using flow cytometry 
Blood was collected in 3.2% buffered citrate bottle and transferred immediately from cardiac 
catheterization laboratory to the haematology laboratory. The samples were centrifuged twice 
at 5,000 g for 5 minutes to obtain platelet-poor plasma (PPP) which was stored at –80o 
Celsius for later analyses of microparticle (MP) estimation and enzyme-linked 
immunosorbent assay (ELISA) studies. MPs were sedimented from 200μL of PPP after 
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centrifugation at 17,000 g for 60 minutes and resuspended in AnV binding buffer (BD 
PharMingen, Oxford, UK). The MP pellets were labelled and characterised with fluorescent 
monoclonal antibodies: fluorescein isothiocyanate (FITC) or Phycoerythrin (PE) labelled 
annexin V, CD62E, CD54, CD105, CD31, CD66b, CD14, TF (clone VD8, American 
Diagnostica), P-selectin (CD62P) CD42a. Using this methodology we defined the following 
types of microparticles: total AnV+ MP, platelet derived MP (PMP; AnV+CD42a+), 
endothelial derived MP (EMP; dual positive for AnV+ and CD62E or CD105; or 
AnV+CD42a-CD31+), neutrophil derived MP (NMP; AnV+CD42a-CD66b+) and tissue 
factor positive monocyte-derived MP (MMP; AnV+CD14+TF+). The samples were 
incubated in the dark for 15 minutes at room temperature prior to analysis by flow cytometry 
using FACS caliber machine (BD Pharmingen) (27). The 1μm beads are used for gating the 
MPs and 3μm beads are used for enumeration. To obtain optimal forward and side scatter 
instrument settings for MP, 1μm and 3μm latex beads (Sigma) were run concurrently with the 
microparticle samples. Logarithmic forward and side scatter plots were obtained. Gates were 
then set to include particles less than approximately 1.5μm, but to exclude the first forward 
scatter channel containing maximal noise. Particles less than 1.5μm in size and binding 
annexin V were then gated, and histograms obtained for this gated population for binding to 
individual monoclonal antibodies to determine the cell of origin of the MP. To convert flow 
cytometer counts to an estimate of the number of MP per ml of plasma, a predetermined 
number (always 200000, calculated as per manufacturer recommendations) of 3μm latex 
beads (Sigma) was divided by the number of 3μm beads counted. The absolute number of 
annexin V binding microparticles per ml of plasma was then calculated by multiplying the 
above ratio (200000/number of 3μm beads counted) with the number of MP flow cytometer 
counts, the number of wells into which the plasma sample was divided (7 wells) and divided 
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by the exact volume of plasma (200μl) from which the microparticles were analysed, as 
described by Combes et al(28).  
Preparation of whole blood for platelet-monocyte aggregate (PMA) flow cytometry 
PMA were identified as previously described (29). In brief blood was collected in 3.2% 
sodium citrate bottles with addition of EDTA to block the in vitro calcium dependent PMA 
formation. Following staining with fluorescent monoclonal antibodies, anti-CD61 FITC, anti-
CD62P PE and anti-CD14 PerCP,  and red blood cell lysis with erythrocytes with easy lyse™ 
solution (Dako) samples were washed with 1mL of FACS flow and centrifuged at 300g for 5 
minutes. The supernatant was discarded and the cells resuspended in 500µL of FACS flow 
for immediate flow cytometric acquisition and analysis (FACS Calibur equipped with Cell 
Quest ® software – BD Biosciences, Oxford, UK). Events were acquired on a 2D dot plot of 
CD14 (logarithmic scale abscissa) and SSC height (linear scale ordinate). Monocytes were 
identified as CD14 positive events and distinctive intermediate side scatter height. A 
minimum of 5000 CD14 positive events were acquired from each sample. The monocyte 
population was gated and named as analysis region (R1). To exclude false-positive PMA 
arising from co-incident analysis of free platelets adjacent to, but not directly interacting with 
monocytes, the events with a narrow CD61 width was drawn (R2). Events falling within both 
R1 and R2 regions were subsequently plotted onto another 2D dot-plot arraying CD61 FITC 
signal height (logarithmic scale abscissa) and CD62P PE (logarithmic scale ordinate). Double 
positive CD14+ and CD61+ events were consider as total PMA and expressed as percentage 
of the total monocytes. P-selectin positive PMA (CD62P+PMA) were identified as triple 
positive CD14+CD61+CD62P+ events and were expressed as a percentage of the total PMA. 
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Measurement of plasma TNF-α, IL-6, hs-CRP, SAA and Troponin T  
Plasma TNF-α and IL-6 levels were measured using a quantitive sandwich enzyme 
immunoassay technique as per manufacturer instructions (R&D  systems, Europe). CRP was 
measured in plasma using a high sensitivity automated microparticle enhanced latex 
turbidimetric immunoassay (COBAS MIRA; Roche Diagnostics GmbH). SAA was measured 
in plasma using latex nephelometry (BNII autoanalyser; Dade Behring, Marburg, Germany). 
Troponin T was measured from plasma using the Elecsys troponin T high-sensitive assay 
(Roche Diagnostics). 
 
Statistical analyses 
Continuous variables were expressed as medians with interquartile range (IQR). Categorical 
variables were expressed as percentages with 95% confidence intervals. Comparisons 
between patient groups and coronary and right atrial compartments were performed using the 
Mann-Whitney U test. Fisher’s exact test was used for comparison of proportions; and the 
Spearman rank correlation coefficient was used for correlations. Differences with a 2-sided p 
value <0.05 was considered to be statistically significant. All statistical analyses were 
performed with GraphPad Prism 5 statistical software. 
Results 
The demographics and baseline characteristics of the study population are shown in table 1. 
Briefly, the majority of the study population was male (79%). The SA patients were more 
likely to have a medical history of hypertension compared with the ACS group (p=0.01). 
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Levels of MP are higher in the CO than in the RA.  
Table 2 summarises the CO MP levels between the two patient groups. Total AnV+ MP were 
higher in the CO than RA in all patients. The ACS population had higher MPs when 
compared to those with SA (p=0.04). All MP sub-populations, endothelial, monocyte and 
platelet, were consistently higher in the ACS group (Figure 1). Blood from the RA also 
showed similar patterns (Figure 2).  
 
Levels of MPs reflect the clinical presentation 
Total MPs from the CO were higher in the STEMI population compared with NSTEMI 
(p=0.02). PMP, EMP and NMP sub-populations were higher in the STEMI group compared 
to the NSTEMI and SA (Table 3). TF+MMP levels did not differ between the STEMI and 
NSTEMI groups. TF+MMP were lower in the SA group compared with the STEMI and 
NSTEMI groups. Total AnV+MP and the other MP sub-populations (except from TF+MMP) 
did not differ between the NSTEMI and SA groups. Similarly all MP were higher in the RA 
in the STEMI population compared with NSTEMI and SA patients (p=0.02) (Table 4). There 
was no difference in TF+MMP levels between STEMI and NSTEMI. All MP were higher in 
the STEMI group compared with the NSTEMI group. 
 
MP expression during ACS is time dependent 
The median (IQR) ischemic times (defined as time from onset of symptoms to PCI, expressed 
in minutes) in the STEMI and NSTEMI groups were 285 (116-360) and 4320 (2100-6060) 
respectively (p<0.0001). Total and cell specific AnV+MPs, isolated from the CO of the 
NSTEMI group, were inversely correlated  with ischaemic time (Figure 3). Although there 
was a trend for negative correlation between the ischaemic time and all MP groups, the 
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correlation was statistically significant only for the total AnV+MP, PMP and EMP. There 
was no correlation between AnV+MP and ischemic time in the STEMI group. 
 
Platelet activation is a feature of ACS 
Having observed elevated levels of platelet microparticles, (Figures 1-2), further assessment 
of the role of platelets in ACS was undertaken. Levels of activated platelet MPs were 
measured in patients with ACS and SA. Figures 1 and 2 show that AnV+CD42a+CD62P+ 
PMP were much higher in the ACS group compared with the SA group in both the CO and 
RA (p=0.0008 and p=0.001 respectively). We have previously shown that activated platelets 
bind to leukocytes and can be detected as platelet monocyte aggregates (PMA) (30). Levels 
of activated PMA were higher in the ACS group than in the SA group in both the CO 
(p=0.0003) and RA (p=0.04) Figure 5. Soluble P-Selectin was also higher in the ACS group 
compared to the SA (Figure 4), and did not differ between CO and RA. 
 
Inflammatory indices are not good indicators of myocardial injury  
There was a non-significant increase in levels of inflammatory markers in ACS patients as 
compared to those with SA (Table 5). Interestingly, with the exception of IL6, inflammatory 
indices were higher in the RA as compared to the CO. This contrasts with MPs, which were 
always higher in the CO. There was a broad correlation between levels of MPs, inflammatory 
indices and troponin T in ACS but not in SA. IL-6 in particular, correlated with levels of 
AnV+CD31+EMP (r=0.5; p=0.03) and AnV+TF+MMP (r=0.6; p=0.01). (Figure 5)  
  
Discussion 
Our study has shown elevated levels of total MPs and MP subpopulations in CAD. Levels of 
MPs varied across the spectrum of CAD with STEMI cohort demonstrating higher levels 
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followed by NSTEMI and SA. Furthermore, levels were highest in the coronary artery, thus 
indicating culprit lesion as the possible source. Levels of MPs were better at identifying 
patients with severe ACS, than inflammatory markers taken from either the CO or RA.  
Our results are in agreement with previous studies demonstrating elevated platelet and 
endothelial MPs in ACS (31-33). We have also now demonstrated that the levels of leukocyte 
(neutrophil and monocyte) MPs are elevated in ACS.  
We further noted negative correlation between the ischaemic time and total MP, PMP, EMP 
AnV+ MP release in the CO in the NSTEMI group but not in the STEMI group. This could 
be because the PPCI in the STEMI group occurred within hours after the onset of symptoms 
(compared to the PCI in the NSTEMI which occurred days after the onset of symptoms) 
which is probably the peak time of MP expression during ACS. This suggests that, in line 
with previous studies (20,34), there is a peak in MP release during the first 24-48 hours and 
thereafter MP levels fall (35). Arguably, earlier sampling (on admission) of the NSTEMI 
patients would have yielded an expression of MP levels similar to that of the STEMI patients. 
Our observation of high levels of AnV+CD62P+ MP in the CO raises the possibility that 
these could amplify vascular inflammation and thus contribute to lesion progression by 
further recruitment of inflammatory cells expressing P-selectin glycoprotein ligand (PSGL), 
which binds CD62P (P-selectin) (36,37).  Since we also detected high CO AnV+CD62E+ 
MP, almost certainly derived from activated coronary endothelium, it is likely that E-selectin-
PSGL binding could further mediate the interaction between inflammatory cells and activated 
endothelial cells and contribute to lesion progression (38). In addition, the high coronary 
artery neutrophil derived microparticles we observed could further amplify vascular 
inflammation by binding to activated endothelium and resultant endothelial activation (39). 
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Further evidence of the importance of platelets in ACS came from our finding that patients 
with ACS had higher CD62P+PMA and soluble P-selectin compared to patients with SA, in 
both CO and the RA. The role of PMA formation in the pathophysiology of CHD remains 
unknown. Activated platelets express P-selectin on their surface, which mediates the platelet-
leukocyte interaction via the P-selectin-PSGL-1 bond leading to PMA formation with 
leukocyte activation, migration and recruitment at the site of inflammation (40,41). The 
platelet-monocyte interaction via the P-selectin-PSGL-1 pathway further increases the 
adhesive and pro-thrombotic properties of monocytes by up-regulating the expression and 
functionality of beta1 and beta2 integrins (42,43) and by TF expression on the monocyte 
surface respectively (44,45). It has been shown that activated platelets lose their surface P-
selectin despite the fact they continue to circulate and function (46). Therefore PMA 
measurement may represent a more robust marker of platelet activation than detection of P-
selectin on their surface (47,48). Increased PMA levels have been observed in patients with 
stable angina (49,50), ACS patients  (51) and also after coronary interventions (52). Studies 
in patients with ACS who underwent PCI after administration of glycoprotein IIb/IIIa 
inhibitors have shown that inhibition of platelet adhesion and activation via glycoprotein 
IIb/IIIa inhibitors leads to PMA formation reduction in addition to the reduction of platelet 
activation and degranulation (52-54). It has also been shown that prevention of platelet 
adhesion to monocyte by blocking the P-selectin-PSGL-1 interaction reduces inflammation 
(55). As well as amplifying inflammation, MP are also prothrombotic (56). Our finding of 
high CO TF+ MMP could implicate their role in clot propagation, since higher levels were 
observed in STEMI and NSTEMI patients than those with SA. A potentially important 
finding is the positive correlation between total AnV+ microparticles and MP subpopulations 
with markers of inflammation. Intracoronary inflammatory markers correlated with total 
AnV+ microparticles and MP subpopulations (including platelets, endothelial and leukocytes 
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derived MP) whilst in the RA markers of inflammation correlated only with endothelial and 
monocyte derived TF+MMP. The fact that in SA the markers of inflammation did not 
correlate with MP formation could suggest a pivotal role of intracoronary inflammation as a 
driver of MP release from the culprit plaque in the pathogenesis of ACS. The observation of 
diverse correlation of MPs and inflammatory markers in the CO and RA could be due to the 
fact different inflammatory markers relate to different activation status of the endothelium. 
Variable EMP profile may indicate variable endothelial activation status (57). In addition, 
due to the small number of patients conclusions cannot be made and further studies needed.  
 
Limitations of the study 
Our study has a number of limitations. Firstly, the study sample was relatively small, making 
the interpretation of correlations less reliable in addition to statistical error (i.e. the 
observation that there was no statistical difference of the inflammatory markers expression 
between ACS and SA patients). Secondly, the effects of antiplatelet and anticoagulant 
therapy on MP production, even though standardised for all patient groups, and their 
prothrombotic activity (i.e. measuring TF activity which was not done in this study) was not 
fully analysed and needs further study. In addition sampling of the infarct related artery 
proximally to the culprit lesion or sampling of a bystander coronary artery could have 
strengthened our hypothesis that the culprit atheromatous coronary plaque is the predominant 
source of microparticle release. We also acknowledge the fact that our flow cytometry 
protocol is not according to international society of thrombosis and haemostasis 
recommended protcols. 
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Conclusions 
Future improvements in outcomes for patients with ACS will come from earlier recognition 
of the disease and a better understanding of its pathogenesis. While there has been 
considerable focus on the role of inflammation in ACS, we and others have failed to find that 
inflammatory markers alone identify patients with ACS as compared to SA. MPs appear to be 
a sensitive indicator of disease activity, both within the coronary artery and within the 
systemic circulation. This may reflect the local genesis of the MPs but may also indicate an 
important role for MPs in the pathogenic processes operating in ACS. Future studies should 
now address the potential for using MPs to characterise the nature and severity of ACS and 
explore the potential for modulating MP mediated pathogenic mechanisms to improve the 
outcome of patients with coronary vascular disease.  
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Figure 1. Differences of the total AnnexinV+ Microparticles (AnV+MP) and MP 
subpopulations in the coronary artery (CO) between the two groups, acute coronary 
syndrome (ACS) and stable angina (SA). Statistical analysis performed using the Mann-
Whitney U test. MP (microparticles), PMP (platelet derived microparticles), EMP 
(endothelial derived microparticle), NMP (neutrophil derived microparticle), MMP 
(monocyte derived microparticle). 
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Figure 2. Differences of the total AnnexinV+ Microparticles (AnV+MP) and MP 
subpopulations in right atrium (RA) in the acute coronary syndrome (ACS) and stable angina 
(SA) groups. Statistical analysis performed using the Mann-Whitney U test. MP 
(microparticles), PMP (platelet derived microparticles), EMP (endothelial derived 
microparticle), NMP (neutrophil derived microparticle), MMP (monocyte derived 
microparticle). 
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Figure 3. Negative correlation between the ischemic time and AnnexinV+ Microparticles 
(AnV+ MPs) in the coronary artery in the non-ST-segment elevation myocardial infarction 
group suggesting a time dependant mode of MP expression during acute coronary syndrome. 
MP (microparticles), PMP (platelet derived microparticles), EMP (endothelial derived 
microparticle). 
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Figure 4. Differences in total platelet monocyte aggregates (PMA), CD62P+PMA and soluble 
p-selectin in the acute coronary syndrome (ACS) and stable angina (SA) groups. Total PMA 
were expressed as percentage of the total monocytes. P-selectin positive PMA 
(CD62P+PMA) were expressed as percentage of the total PMA. Statistical analysis 
performed using the Mann-Whitney U test. PMA (platelet monocyte aggregates) 
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Figure 5. Positive correlation between AnnexinV+ Microparticles (AnV+MP) and markers of 
inflammation Interleukin (IL-6) in the right atrium (RA) in the acute coronary syndrome 
(ACS) group. EMP (endothelial derived microparticle), MMP (monocyte derived 
microparticle), IL-6. 
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ACS SA p value
Number of patients (n) 37 11
Age (mean), years 60 61 0.8
Male 29 9 0.7
Female 8 2 0.7
Risk Factors
Hypertension 14 9 0.01
Diabetes 9 2 0.9
Dyslipidaemia 19 4 0.4
Smoking 13 2 0.5
Family History of CHD 17 4 0.7
Angiographic characteristics 0.7
1 vessel disease 25 6
2 vessel disease 7 3
3 vessel disease 5 2
Culprit vessel 0.3
Left Anterior Descending 14 6
Left Circumflex 7 0
Right Coronary 16 5  
Table 1. Baseline characteristics, demographics and angiographic data of the acute coronary 
syndrome (ACS) and stable angina (SA) groups. Fisher exact test was used for comparison of 
proportions between the groups. Coronary heart disease (CHD). 
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CO RA
ACS SA ACS SA
Median (IQR) Median (IQR) p value Median (IQR) Median (IQR) p value
Total AnV+ MP 5.22 (3.11-8.22) 2.51 (0.91-5.75) 0.04 1.4 (0.67-4.02) 1.11 (0.14-1.49) 0.1
CD42a+AnV+ PMP 1.61 (0.89-3.23) 0.71 (0.20-1.28) 0.03 0.67 (0.24-2.56) 0.28 (0.02-0.60) 0.02
CD62P+CD42a+AnV+ PMP 0.4 (0.2-1.7) 0.08 (0.02-0.15) 0.0008 0.17 (0.06-0.61) 0.03 (0.001-0.04) 0.001
CD62E+CD42a-AnV+ EMP 0.65 (0.225-1.06) 0.17 (0.07-0.67) 0.03 0.12 (0.03-0.42) 0.04 (0.009-0.07) 0.02
CD54+CD42a-AnV+ EMP 0.42 (0.18-0.76) 0.11 (0.05-0.18) 0.001 0.07 (0.02-0.15) 0.009 (0.004-0.04) 0.008
CD105+CD42a-AnV+ EMP 0.76 (0.29-1.01) 0.38 (0.07-0.77) 0.04 0.11 (0.04-0.38) 0.07 (0.008-0.18) 0.1
CD31+CD42a-AnV+ EMP 0.51 (0.31-1.15) 0.24 (0.10-0.33) 0.005 0.08 (0.02-0.26) 0.05 (0.003-0.09) 0.09
CD66b+CD42a-AnV+ NMP 0.14 (0.07-0.39) 0.04 (0.03-0.20) 0.04 0.08 (0.02-0.12) 0.01 (0.002-0.02) 0.004
CD14+TF+AnV+ MMP 0.17 (0.07-0.27) 0.07 (0.03-0.15) 0.02 0.07 (0.02-0.18) 0.03 (0.005-0.05) 0.02  
Table 2. Differences of the total AnV+MP and MP subpopulations (*10⁶/ml of plasma) 
between the acute coronary syndrome (ACS) and stable angina (SA) groups in the coronary 
(CO) and right atrium (RA). Statistical analysis performed using the Mann-Whitney U test. 
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CO
STEMI NSTEMI SA Kruskal-Wallis test 
Median (IQR) Median (IQR) Median (IQR) p value
Total AnV+ MP 5.35 (3.00-12.0) 2.85 (1.96-4.50) 2.51 (0.91-5.75) 0.04
CD42a+AnV+ PMP 2.20 (0.72-4.81) 1.05 (0.51-1.71) 0.71 (0.20-1.28) 0.04
CD62P+CD42a+AnV+ PMP 0.95 (0.28-2.45) 0.18 (0.11-0.42) 0.08 (0.02-0.15) 0.0003
CD62E+CD42a-AnV+ EMP 0.69 (0.18-1.70) 0.33 (0.11-0.67) 0.17 (0.07-0.67) 0.02
CD66b+CD42a-AnV+ NMP 0.17 (0.08-0.44) 0.11 (0.04-0.21) 0.04 (0.03-0.20) 0.01
CD54+CD42a-AnV+ EMP 0.64 (0.28-0.88) 0.20 (0.11-0.34) 0.11 (0.05-0.18) 0.0008
CD105+CD42a-AnV+ EMP 0.76 (0.37-1.91) 0.45 (0.11-0.78) 0.38 (0.07-0.77) 0.02
CD31+CD42a-AnV+ EMP 0.75 (0.35-1.40) 0.32 (0.09-0.47) 0.24 (0.10-0.33) 0.0005
CD14+TF+AnV+ MMP 0.15 (0.07-0.31) 0.18 (0.07-0.25) 0.07 (0.03-0.15) 0.04  
Table 3. Differences of microparticles expression (*10⁶/ml of plasma) in the three groups in 
the coronary artery (CO). MP levels expressed as medians with interquartile range (IQR). 
Statistical analysis performed using Kruskal-Wallis test. 
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RA
STEMI NSTEMI SA Kruskal-Wallis test 
Median (IQR) Median (IQR) Median (IQR) p value
Total AnV+ MP 1.72 (0.64-5.78) 0.29 (0.11-1.2) 1.11 (0.14-1.49) 0.058
CD42a+AnV+ PMP 0.84 (0.26-3.97) 0.11 (0.03-0.54) 0.28 (0.02-0.60) 0.025
CD62P+CD42a+AnV+ PMP 0.17 (0.07-0.66) 0.03 (0.005-0.14) 0.03 (0.001-0.04) 0.001
CD62E+CD42a-AnV+ EMP 0.23 (0.06-0.44) 0.02 (0.01-0.12) 0.04 (0.009-0.07) 0.009
CD66b+CD42a-AnV+ NMP 0.08 (0.04-0.14) 0.01 (0.004-0.09) 0.01 (0.002-0.02) 0.002
CD54+CD42a-AnV+ EMP 0.07 (0.05-0.16) 0.04 (0.008-0.10) 0.009 (0.004-0.04) 0.007
CD105+CD42a-AnV+ EMP 0.16 (0.06-0.43) 0.04 (0.01-0.09) 0.07 (0.008-0.18) 0.02
CD31+CD42a-AnV+ EMP 0.11 (0.04-0.31) 0.04 (0.01-0.20) 0.05 (0.003-0.09) 0.1
CD14+TF+AnV+ MMP 0.09 (0.02-0.41) 0.05 (0.01-0.13) 0.03 (0.005-0.05) 0.04  
Table 4. Differences of microparticles expression (*10⁶/ml of plasma) in the three groups in 
the right atrium (RA). MP levels expressed as medians with interquartile range (IQR). 
Statistical analysis performed using Kruskal-Wallis test. 
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ACS SA
RA CO RA CO
Median (IQR) Median (IQR) p value Median (IQR) Median (IQR) p value
IL-6 (pg/mL) 5.03 (1.53-13.06) 6.3 (3.7-13.6) 0.01 2.29 (1.53-6.26) 2.01 (0.38-16.1) ns
SAA (ml/L) 5.5 (2.6-12.8) 3.3 (1.8-9.5) 0.003 2.5 (1.6-2.8) 2.4 (1.1-2.72) ns
hs-CRP (mg/L) 2.8 (0.9-6.1) 2.1 (0.77-5.82) 0.0005 0.8 (0.7-2.1) 0.8 (0.57-1.55) ns
TNF-α (pg/ml) 18.77 (7.4-33.92) 14.62 (5.9-28.86) 0.03 22.77 (8.61-38.98) 9.16 (6.92-30.83) ns  
Table 5. Differences of the inflammatory markers (medians (IQR)) between the acute 
coronary syndrome (ACS) and stable angina (SA) patients in the coronary (CO) and right 
atrium (RA). Statistical analysis performed using the Wilcoxon test. IL-6 (interleukin 6), 
SAA (serum amyloid A), TNF-α (tumour necrosis alpha) and hs-CRP (high sensitivity C-
reactive protein). 
ACCEPTED MANUSCRIPT
